LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (Nasdaq: FFIE) (“Faraday Future”, “FF” or “Company”), a…
Seraphic’s First of its Kind Enterprise Browser Security Solution Recognized as Outstanding Best Threat Detection…
Completes Business Combination and Becomes Publicly Traded Company Third Quarter Fiscal 2023 Net Revenues Totaled…
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
SEATTLE, May 22, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging…
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in…
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in…
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to…
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
CHASKA, Minn., May 22, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (“Lifecore” or the “Company”),…
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the…
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq:…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM…
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended…
TERN-601 (oral GLP-1) program in obesity on track to initiate Phase 1 clinical trial in…